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Abstract
Patients with gastroesophageal reflux disease (GERD) present with comorbid complications
with implications for healthcare utilization. To date, little is known about the effects of GERD
treatment with a proton-pump inhibitor (PPI) on patients’ subsequent healthcare utilization
for acute respiratory infections (ARIs). This population-based study compared ARI episodes
captured through outpatient visits, one year before and one year after GERD patients
received PPI treatment. We used retrospective data from the Longitudinal Health Insurance
Database 2005 in Taiwan, comparing 21,486 patients diagnosed with GERD from 2010 to
2012 with 21,486 age-sex matched comparison patients without GERD. Annual ARI episodes represented by ambulatory care visits for ARI (visits during a 7-day period bundled
into one episode), were compared between the patient groups during the 1-year period
before and after the index date (date of GERD diagnosis for study patients, first ambulatory
visit in the same year for their matched comparison counterpart). Multiple regression analysis using a difference-in-difference approach was performed to estimate the adjusted association between GERD treatment and the subsequent annual ARI rate. We found that the
mean annual ARI episode rate among GERD patients reduced by 11.4%, from 4.39 before
PPI treatment, to 3.89 following treatment (mean change = -0.5 visit, 95% confidence interval (CI) = (-0.64, -0.36)). In Poisson regression analysis, GERD treatment showed an independent association with the annual ARI rate, showing a negative estimate (with p<0.001).
The study suggests that GERD treatment with PPIs may help reduce healthcare visits for
ARIs, highlighting the importance of treatment-seeking by GERD patients and compliance
with treatment.
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Introduction
Gastroesophageal reflux disease (GERD), which often presents with symptoms of heartburn
and acid regurgitation, is a common chronic disorder in many countries [1]. In Western populations, about 10%~20% of the population report having GERD symptoms at least weekly
[2,3], while in East Asia, the prevalence ranges between 2.5%~7.8% [2,4,5]. A rising trend of
GERD prevalence is documented in population-based surveys, potentially attributable to aging
populations, the obesity epidemic and the associated dietary and physical activity changes, and
changes in sleep patterns [6,7]. GERD is documented to markedly impair general well-being,
quality of life, and work productivity, in addition to requiring substantial medical care
resources [2,8].
The most overt complications of GERD are esophageal, primarily due to injury. The complications include erosive esophagitis with or without acute or chronic gastrointestinal hemorrhage, esophageal stricture, and Barrett’s esophagus [9]. In addition, patients with GERD
frequently report extra-esophageal symptoms ranging from pharyngitis, laryngitis, asthma,
and hoarseness to more serious pulmonary aspiration syndromes, including bronchiectasis,
lung abscesses, and recurrent pneumonias [10,11]. The airways, in contrast to the distal esophagus, are not protected by antireflux clearance mechanisms or intrinsic mucosal properties.
One prospective study of patients categorized into GERD and non-GERD patients by endoscopy findings, reported a strong relationship between gastroesophageal reflux symptoms and
various respiratory disorders [12]. Among patients with erosive esophagitis, respiratory symptoms were more prevalent, with evidence of a direct association between the severity of airway
obstruction and that of GERD symptoms.
GERD patients, presenting with esophageal or extra-esophageal symptoms, have more
comorbid complications that require more healthcare visits, thus incurring higher healthcare
costs [13]. Anti-secretory agents, such as proton pump inhibitors (PPIs) provide both symptom relief and healing of short- and long-term erosive esophagitis [14]. Few studies have
examined whether GERD treatment ameliorates the non-esophageal complications and comorbidities. Littner et al. reported that medical treatment of acid reflux disease had no significant effects on daily asthma symptoms or pulmonary function [15]. To date, little is known
about whether treating GERD patients with a PPI affects subsequent occurrences of acute
respiratory infections or healthcare utilization for these episodes. This population-based study
used nation-wide longitudinal data to examine changes in the annual acute respiratory infection (ARIs) episode rate identified through ambulatory care visits, one year before and one
year after adult GERD patients received PPI treatment.

Methods
Database
Data for this study were retrieved from the Longitudinal Health Insurance Database 2005
(LHID2005). The LHID2005 includes registration files and filed medical claims for 1,000,000
enrollees randomly selected from all enrollees listed in the 2005 Registry of Beneficiaries under
the Taiwan National Health Insurance (NHI) program (n = 23.72 million). Specifically, in
1995, Taiwan initiated its NHI program to grant universal coverage to all citizens, with a generous benefit package, low co-payments, and a free choice of widely-dispersed networks of
healthcare providers. Monthly claims summaries in the claims dataset consist of outpatient
and inpatient claims for every NHI beneficiary, details of inpatient and drug orders, the contracted medical facility used, and board-certified specialists who attended the patient. While
the diagnostic coding accuracy cannot be ascertained, claims accuracy is considered to be
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generally accurate due to the NHI Bureau’s routine practice of sample verification of each hospital’s claims using medical charts, followed by punitive measures for coding infractions.
Many researchers have carried out longitudinal studies using the LHID2005 data on the
1,000,000 representative sample of NHI enrollees and published study results in internationally
peer-reviewed journals. The LHID2005 provides a unique opportunity to study the relationship between treating GERD and subsequent healthcare service utilization for ARIs. Because
the study dataset consists of de-identified secondary data released to the researcher community
for research purposes, the study was exempted from full IRB review by the Taipei Medical University Institutional Review Board (TMU-JIRB 201412035).

Study sample
The study included a study group and a comparison group. To identify the study group, we
first selected 33,730 patients with a first-time principal diagnosis of GERD (ICD-9-CM code
530.11 or 530.81) between 1st January 2010 and 31st December 2012 in the LHID2005. We
excluded 559 patients aged <18 years, 162 patients who died during the following year, and
11,523 patients who did not have endoscopy-confirmed GERD diagnosis or those with endoscopy-confirmed diagnosis who had not received a prescription PPI for at least 30 days following diagnosis. In Taiwan, eligibility for NHI reimbursement for PPI prescriptions for GERD
requires completion of a peer review process, conducted by a gastroenterologist sub-committee in the NHI Administration. The committee assesses the patient’s eligibility for PPIs based
on clinical symptoms and the endoscopy imaging evidence, applying the Los Angeles Classification of Esophagitis criteria for a GERD diagnosis. Our final analytic sample of study patients
consisted of 21,486 GERD patients, and we assigned their first ambulatory care visit with a PPI
prescription for GERD as their index date.
We selected comparison patients from the remaining LHID2005 enrollees aged  18 years
using the SAS proc survey select program for comparison patient selection (SAS System for
Windows, vers. 8.2, SAS Institute, Cary, NC). We excluded all enrollees with a GERD diagnosis during the study years, and those who died during the year 2013 (to ensure equal follow-up
periods (1 year). We then randomly selected 21,486 patients matched with the study patients
on sex, age group (18~29, 30~39, 40~49, 50~59, 60~69, and >69 years), and year of index date
of the corresponding study patient. For the study group, the year of the index date was defined
as the year in which the study group was assigned their first ambulatory visit for GERD treatment. Comparison patients were selected based on a match of their year of utilization of any
ambulatory care with the year of GERD treatment of a study patient (of the same sex and age
group). For the comparison patients, we defined the date of their first healthcare use in the
index year as their index date.
The final study sample consists of 42,972 patients. We calculated the mean number of
ambulatory care visits (including all outpatient visits to hospitals and clinics) for ARIs (ICD9-CM codes 460~466) for each patient within a 1-year period before and after their index date,
and bundled all ARI visits within 7 days into one episode (to avoid multiple counting of a single ARI episode). Although most ARIs are self-limited viral infections, medications such as
antibiotics may be prescribed for the management of ARIs.

Statistical analysis
We used the SAS statistical package (SAS System for Windows, vers. 8.2) and SPSS statistical
software (IBM SPSS Statistics for Windows, Version 20.0.) for analyses. We used paired t-tests
to compare mean annual ambulatory ARI episodes during the year before and after the index
date. We used the difference-in-difference method to compare the average change over time
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Fig 1. Distribution of patients by annual number of for acute respiratory infection episodes classified by patient group and study
period: (A) GERD patients before the index date (B) GERD patients after the index date (C) Comparison patients before the index
date (D) Comparison patients after the index date.
doi:10.1371/journal.pone.0172436.g001

in the annual ARI episode rate for the GERD group, and further, compared the before-after
change in the GERD-treated group with that of the comparison group. Based on the distribution of ARI episodes in the sample (Fig 1), we conducted Poisson regression analysis, using the
difference-in-difference method to estimate the independent association between GERD treatment and annual ARI episode rate, adjusted for age, sex, monthly income, geographic region,
and residential urbanization level. The difference-in-difference estimate of the impact of
GERD treatment on the ARI episode rate was assessed by the estimate for the interaction term
between GERD treatment (yes vs. no) and time period (before vs. after). We had no missing
data on the sociodemographic covariates, as these are required claims form items to qualify for
reimbursement. Differences were considered significant based on a two-sided p value of 0.05.
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Results
The sample mean age was 52.9 years (±15.7) for the total sample, 53.0±15.4 years for study
group, and 52.9±15.9 years for the comparison group. Table 1 shows that after matching for
sex, age group, and the index year, chi-square tests showed slight, though statistically significant differences in monthly income, geographic region, and residential urbanization level
between the GERD sample and comparison sample (all p<0.001). The GERD group had
somewhat more urbanized patients and had slightly higher income than the non-GERD
group.
Table 2 presents the mean annual ARI episodes per patient during the year before and
after the index date among the study group and comparison group. GERD patients’ mean
ARI episode rate decreased from 4.39 during the year prior to the index date to 3.89 after the
index date (mean change = -0.5, 95% confidence interval (CI) = (-0.64, -0.36)). Among comparison patients, we observed a slight increase in the annual ARI episode rate after the index
date (mean change = 0.08, 95% CI = (0.01, 0.15)). Fig 1 shows the distribution of patients by
their annual ARI episode rate in the before-after index date years, classified by patient
group. The graph shows a reduction in the annual ARI episode rate among GERD patients.
In contrast, among the comparison patients, the ARI episode rate was similar in the two
periods.
Table 3 shows the results of Poisson regression analysis using the difference-in-difference
method. The coefficient of the interaction term between GERD treatment and time period was
statistically significant and negative, after adjusting for patient’s age, sex, monthly income,
urbanization level, and geographic region (estimate = -0.156, 95%CI = (-0.177, -0.134)).

Table 1. Demographic characteristics of sample patients (N = 42,972).
Variable

Male

Patients with
gastroesophageal reflux
disease
n = 21,486

Comparison patients
n = 21,486

Total no.

Column %

Total no.

Column %

9812

45.7

9812

45.7

53.0 ± 15.4

Age, mean, SD (years)

52.9 ± 15.9

>0.999
0.308
<0.001

Urbanization level
1 (most urbanized)

7388

34.4

6878

32.0

2

6116

28.5

5868

27.3

3

3202

14.9

3530

16.4

4

2674

12.4

2814

13.1

5 (least urbanized)

2106

9.8

2396

11.2

10,670

49.6

10,222

47.6

Central

5670

26.4

4976

23.2

Southern

4678

21.8

5842

27.2

Eastern

468

2.2

446

2.0

NT$0~15,840

7626

35.5

8020

37.3

NT$15,841~25,000

7728

36.0

7728

36.0

NT$25,001

6132

28.5

5738

26.7

<0.001

Geographic region
Northern

p value

<0.001

Monthly income

Note: The exchange rate in 2010 was US$1.00  New Taiwan (NT)$30.
doi:10.1371/journal.pone.0172436.t001
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Table 2. Number of annual episodes of acute respiratory infection per patient during the year before and after the index date, among study
patients (with gastroesophageal reflux disease, GERD) and comparison patients.
Before

After

Difference (AfterBefore)

Paired t-test p
value

Mean annual ARI
episodes

SD

Mean annual ARI
episodes

SD

Mean (95% CI)

GERD patients who received
treatment

4.39

7.50

3.89

7.17

-0.50 (-0.64~ -0.36)

<0.001

Comparison patients

2.38

3.83

2.47

4.10

0.08 (0.01~0.15)

0.021

SD, standard deviation.
CI, confidence interval.
doi:10.1371/journal.pone.0172436.t002

Discussion
Based on reviewing the documented literature, this is the first study to examine the benefit of
treating GERD with a PPI in reducing the ARI complications of GERD. Specifically, while a
slight increase of 0.08 ARI episodes per year was observed among patients without GERD, the
annual ARI rate among GERD patients dropped significantly, by 11.4%, from a mean of 4.39
episodes during the year before treatment to 3.89 after treatment with a PPI. This reduction is
substantial, considering that ARI was ranked among the top five contributors to healthcare
spending in Taiwan in 2014 (approximately NT$20 billion). The univariate findings are corroborated by multivariate Poisson regression analysis, which showed that GERD treatment
was independently associated with a significant reduction in ARI episodes compared to the
same patients’ rate before treatment and to the demographically comparable general population sample.
GERD is a common disease that causes coexisting or non-concurrent esophageal and extraesophageal symptoms. Respiratory symptoms associated with GERD are some of the most
widely prevalent and challenging extra-esophageal manifestations. For instance, GERD is the
third leading cause of cough, affecting an estimated 20% of GERD patients [16,17]. GERDrelated coughs mostly occur after an upper respiratory tract infection [18]. There is increasing
epidemiological evidence of a strong relationship between reflux episodes and respiratory
symptoms [10,12]. In a study that recruited 515 patients presenting to gastroenterology clinics
in Saudi Arabia [12], a significant difference was observed in the prevalence of all respiratory

Table 3. Poisson regression analysis, difference-in-difference method: Impact of receiving treatment for gastroesophageal reflux disease (GERD)
on the annual number of acute respiratory infection episodes.
Dependent variable: Total Number of acute respiratory infection episodes
Parameter estimate

Standard error

95% CI

P value

GERD treatment

0.614

0.008

0.598~0.629

<0.001

Time period (after vs. before)

0.035

0.009

0.017~0.052

<0.001

GERD treatment x Time period

-0.156

0.011

-0.177~ -0.134

<0.001

Age

-0.003

0.000

-0.003~ -0.002

<0.001

Male

-0.137

0.006

-0.154~ -0.133

<0.001

Urbanization level

-0.001

0.002

-0.005~0.004

0.821

Geographic region

0.035

0.003

0.029~0.041

<0.001

Monthly income

0.019

0.003

0.013~0.026

<0.001

Note: The exchange rate in 2010 was US$1.00  New Taiwan (NT)$30.
doi:10.1371/journal.pone.0172436.t003
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symtpoms among patients with abnormal endoscopic findings (63%), compared to 37.2%
among those with normal endoscopy. A positive correlation between the severity of airway
obstruction as detected by FEV1 and FEV1/FVC and GERD symptoms was also observed.
GERD patients with extra-esophageal manifestations or complications, including respiratory diseases, have significantly higher healthcare utilization with associated higher costs [13].
These findings highlight the need for specific evidence on the impact of GERD treatment on
non-esophageal complications. Acid-suppressive therapy, especially with PPIs, is generally the
first-line approach for treating GERD. The efficacy of PPI therapy in relieving heartburn
symptoms and healing erosive esophagitis [19,20], is validated by normal endoscopy findings
among most patients with GERD following PPI treatment [4,21]. However, GERD treatment
has not been impactful in resolving chronic symptoms of cough, hoarseness, and globus
[22,23]. In a review of 12 randomized-controlled trials, a null finding was reported regarding
overall symptom improvement in asthma patients following the medical treatment of GERD
[24]. Our study presents a new finding regarding the impact of GERD treatment with PPIs on
ARI episode rates, with the potential to reduce healthcare utilizaiton on this account.
There are several plausible reasons for fewer ambulatory visits for ARI following GERD
treatment. GERD is recognized as a plausible cause of respiratory symptoms [25]. This may be
due to the direct noxious effects of gastric contents on the mucosal surfaces of the upper airways (pharynx, larynx, middle ear, and nasosinusal complex) and lower airways (tracheobronchopulmonary tree). Lacking protection from the antireflux clearance mechanisms and
intrinsic mucosal properties present in the lower esophagus, the airways may be more readily
damaged and functionally impaired by the reflux of gastric contents beyond the esophagus.
Persisting reflux episodes, often produced by the transient relaxation of the lower esophageal
sphincter, causing reflux contents to spread beyond the esophagus into the airways could plausibly cause respiratory symptoms [12,26]. Acid-suppressive medication reduce reflux episodes,
and may allow the airways to heal, as well as restore their normal anatomic and functional
mechanisms due to stopping the stimulation and damage by regurgitated gastric juices. These
effects may clinically manifest as a reduction in ARI episodes, in turn reflected in reduced
ambulatory care visits for ARIs, the measure that we used in this study. A second biological,
direct effect of PPI may be activated: the known attenuation of neutrophil adherence to endothelial cells by PPIs via inhibiting the expression of adhesion molecules, which is thought to
exert an anti-inflammatory effect [27]. Because inflammatory mediators in the airways are elevated in many chronic respiratory conditions such as post-nasal drip, asthma and GERD [28],
it is plausible that PPI treatment of GERD initiates an anti-inflammatory process that reduces
airway inflammation and reduces the risk of airway infections. It is documented that even a
single reflux episode extending beyond the esophagus may be sufficient to trigger respiratory
signs and symptoms [12].
One limitation of our study is that the duration of GERD symptoms before seeking medical
treatment was not available. However, this limitation would result in underestimation of the
GERD treatment effect, as the study patients’ initial reflux episodes most likely, started less
than a year before the GERD diagnosis was made (which allowed them to be included in the
study; patients with pre-exisiting GERD diagnosis were excluded from the study). Comparing
their ARI healthcare utilization during the year before and after GERD treatment would have
underestimated the benefits of GERD medication on ARIs. Despite this potential effect, our
study finds a measurable and significant reduction in ARI episodes following GERD treatment
with PPIs.
There are significant implications of the study which highlights the importance of educating
patients to seek medical treatment for GERD syndromes. GERD is defined as “a condition
which develops when the reflux of stomach contents causes troublesome symptoms and/or
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complications” [1]. The patient-centered approach emphasizes the imperative to increase
GERD symptom awareness among the general population and to encourage patients to seek
prompt medical treatment. The population should be educated that once the symptoms of
heartburn and regurgitation impact their regular activities of living and quality of life, timely
treatment is important to relieve symptoms and minimize the complications, including ARIs.
Studies suggest that PPI compliance is generally poor [29], with about 40%~50% of patients
not taking the prescribed PPIs correctly [30,31]. It is also documented that both healthcare
resource use and costs were reduced among PPI compliants compared to their pre-PPI period,
and compared to noncompliant patients [32]. Patient education needs to be reinforced for successful PPI treatment.
A particular strength of this study was the use of a longitudinal, nationwide, populationbased sample cohort, with comprehensive follow-up data due to mandatory enrollment in Taiwan’s NHI program. Selection bias may, therefore, be minimal. Another strength is that the
GERD diagnosis was endoscopy-confirmed, and additionally validated by an independent
expert sub-committee (constituted to approve PPI use). We also limited the study criteria to
only include patients with a substantial duration of GERD treatment (claim for a PPI for more
than 30 days). These inclusion criteria protect against misclassification bias and ensure clear
separation of study and comparison patients on the index diagnosis.
There were some study limitations. One inherent limitation of using claims data is that the
study gets limited to pateints who sought treatment for GERD and ARIs. Due to the wide
range of GERD manifestations and subjective preferences for action-taking and symptom perceptions, the real prevalence of pathological reflux disease is thought to be underestimated
[33]. However, the relevance of this issue for our study findings may be mitigated. Individual
behaviors of healthcare utilization may be fairly consistent over time. Pre- vs. post-treatment
comparisons among the same groups of patients, with and without GERD should therefore
attenuate this source of concern. Second, the study data do not permit studies of healthcare
cost differences due to GERD treatment because claims data do not have information on
GERD severity. Aggregating claims costs without accounting for severity would bias the
results. Third, our estimates of healthcare utilization may be biased due to not accounting for
over-the-counter medications used for GERD. This may be mitigated by the fact that Taiwan
has a universal coverage, National Health Insurance program since 1995, with very low out-ofpocket payments which facilitates patient access to providers. Further, the high cost of PPI
medications may discourage over-the-counter purchase. Another limitation is the lack of data
on medication compliance, a documented phenomenon with PPI medication. However, suboptimal compliance should bias the findings towards the null. Another limitation is that
despite a finding of reduced ARI rates following PPI use, it does not mean that the PPI treatment was adequate. It is possible that optimal GERD treatment may reduce the ARI episode
rate further on a population-basis. On a precautionary note, assessing the magnitude of ARI
reduction should be in the context of the benefits and risks of PPI treatment (e.g., side effects
and complications). Finally, again due to the limitations of claims data, our study was unable
to account for other important risk factors such as the body-mass index, cigarette smoking,
alcohol consumption, other medications being used, and dietary habits (e.g., soda and coffee
consumption) that may impact both GERD and ARIs [34,35]. Two study features mitigate this
concern. While data on co-morbidities and other medications were unavailable, the random
selection of age-sex matched comparison patients may have resulted in a reasonably representative sample of the non-GERD general population. Further, comorbidities, other medications,
and life style factors within the same individual may be stable over a 2-year period, and less
critical to adjust for, given our use of a pre- vs. post-treatment comparison approach.
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GERD has increasingly been identified as a potential cause of respiratory symptoms, translating into substantial clinical and economic burden for healthcare systems. This large-scale
population-based cohort study suggests that there are potential benefits of GERD treatment in
reducing healthcare visits for ARIs. More studies, particularly stratifying patients by the nature
and severity of both ARI and GERD symptoms, are needed to validate our findings and produce more robust evidence for clinical practice and policy changes. Cost effectiveness, costbenefit and quality of life studies are also essential to evaluate the full impact of PPI treatment
on patients’ health, quality of life, and healthcare expenditures.
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